Martin McKibbin

Employment

• Leeds Teaching Hospitals NHS Trust

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (44)

• Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study
  Eye 2026 DOI: 10.1038/s41433-025-04213-2
  +Save
• Diagnostic discovery of structural variants causing foveal hypoplasia using SVRare and long-read nanopore sequencing
  European Journal of Human Genetics 2026 DOI: 10.1038/s41431-026-02190-y
  +Save
• Early detection of neovascular age-related macular degeneration in the second eye reduces intravitreal treatment burden: FASBAT report 2
  Eye 2026 DOI: 10.1038/s41433-025-04210-5
  +Save
• Diagnostic Discovery Of Structural Variants causing Foveal Hypoplasia Using SVRare and Long Read Nanopore Sequencing
  2026 DOI: 10.21203/rs.3.rs-8969358/v1
  +Save
• The Royal College of Ophthalmologists National Ophthalmology Database age-related macular degeneration (AMD) audit: report 1, associations with socio-economic deprivation in neovascular AMD
  Eye 2026 DOI: 10.1038/s41433-026-04382-8
  +Save
• The Royal College of Ophthalmologists National Ophthalmology Database Age-Related Macular Degeneration Audit, Report 2: Baseline Characteristics, the Care Pathway and 12-Month Visual Acuity and Safety Outcomes for 54,882 Eyes Starting Treatment for Neova…
  Ophthalmologica 2026 DOI: 10.1159/000552289
  +Save
• The Royal College of Ophthalmologists National Ophthalmology Database Age-related Macular Degeneration Audit: Report 1, Associations with socio-economic deprivation in neovascular age-related macular degeneration
  2025 DOI: 10.21203/rs.3.rs-7417262/v1
  +Save
• A thematic analysis of patients’ experiences of receiving treatment for Neovascular age-related macular degeneration (nAMD)
  Eye 2025 DOI: 10.1038/s41433-025-03915-x
  +Save
• Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6
  Eye 2025 DOI: 10.1038/s41433-025-03797-z
  +Save
• Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2 mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7
  Eye 2025 DOI: 10.1038/s41433-025-03687-4
  +Save